AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds that produces autophagy-mediated cytotoxicity selectively in cancer cells. The first drug candidate, ABTL0812, is currently in phase 2b/3 clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a tr...
AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds that produces autophagy-mediated cytotoxicity selectively in cancer cells. The first drug candidate, ABTL0812, is currently in phase 2b/3 clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and squamous non-small cell lung cancer in Spain and France.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.